NIPT (Non Invasive Prenatal Screening)

Non-invasive prenatal screening (NIPT) is a prenatal screening method based on the analysis of extracellular DNA. With this method, fetal DNA can be isolated from the peripheral blood sample taken from the mother in a special tube and scanned for chromosomal abnormalities. VeriSeq NIPT v2 is a NIPT test for detecting fetal genomic anomalies using maternal blood sample. It can be applied as early as the 10^th week of pregnancy.

Period of Comprehensive Prenatal Testing with VeriSeq NIPT v2!

Perform with Next Generation Sequencing Technology, VeriSeq NIPT v2 uses whole genome sequencing. In this way, in addition to trisomy 21, trisomy 18 and trisomy 13, all rare autosomal aneuploidies, sex chromosome aneuploidies and deletions and duplications greater than 7 MB in all autosomal chromosomes can be detected.

Genome-wide fetal chromosomal anomaly detection: Comprehensive test menu validated with over 2300 samples
Unmatched performance : High accuracy, fast result
Simple and scalable workflow : Ease of implementation, analysis of 24, 48 or 96 samples